We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases.

2 days ago · Metsera began trading on the Nasdaq Friday under the stock symbol “MTSR.” The stock showed some pop, finishing its first day of trading at $26.50 per share, up 47.2% from the IPO price.

3 days ago · Metsera's most advanced product candidate, MET-097i, an injectable, showed an average weight loss of 11.3% in patients during a mid-stage trial, the company said earlier this month.

5 days ago · Metsera, an obesity drug developer, sold nearly 15.3 million shares at $18 apiece in an offering that ranks as one of the industry’s largest since 2022, according to BioPharma Dive data. Maze, a maker of kidney disease medicines, priced more than 8.7 million shares at $16 each, exceeding the terms it had set earlier this week.

Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.

Jan 7, 2025 · Privately-held biotechnology startup Metsera said Tuesday a long-acting GLP-1 shot it’s developing helped people who are overweight or have obesity lose more weight than placebo recipients in a Phase 2 trial.

Learn about Metsera: a team of experts dedicated to reducing the burden of obesity through cutting-edge NuSH therapies built on 20+ years of peptide engineering research.

Apr 18, 2024 · Metsera is advancing a portfolio of next-generation therapies for obesity and metabolic diseases, including ultra-long acting injectable and oral nutrient stimulated hormone (NuSH) analogs and combinations designed with best-in-class profiles. With a library of over 20,000 NuSH peptide analogs and peptide/antibody conjugates, Metsera aims to ...

NEW YORK, September 24, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today...

NEW YORK, April 18, 2024 -- (BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases,...